 |
|
|
 |
.NEWS FROM SIO
Upcoming Webinar: A Day in the Life: IO for Liver Cancer
Attend our live IO Awareness Week webinar, A Day in the Life: IO for Liver Cancer, presented by SIO and supported by an unrestricted educational grant from Varian, A Siemens Healthineers Company. This 90-minute CME-accredited webinar takes place on Wednesday, 27 October at 7:00 PM EDT. A Day in the Life targets interventional radiologists at any stage of their career, from senior-level physicians to students/trainees. Attendees will learn about the top 10 studies to know for tumor boards, as well as top 10 pearls of wisdom for ablation, embolization, and Y90.
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Society of Interventional Oncology. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
|
|
SIO2022 Annual Scientific Meeting Will Feature Hybrid Format 
With the SIO2022 Annual Scientific Meeting approaching, SIO recognizes the continued importance of holding a safe, enjoyable meeting in San Francisco. We are currently planning to meet in person 3-7 February 2022 with some virtual elements. Click the link below for a letter from SIO President Dr. Matthew Callstrom regarding important safety information for the upcoming conference, for which registration will open later this month.
|
|
SIO Directors Co-Author Consensus Guidelines Following SIO and DATECAN Initiative Results
Members of the SIO Board of Directors co-authored "Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative." The consensus document proposes standardized definitions for a broad range of oncologic outcome measures with recommendations on how to uniformly document, analyze and report outcomes.
This initiative was coordinated by SIO with the Definition for the Assessment of Time-to-Event End Points in Cancer Trials (DATECAN) group. SIO congratulates the authors of this initiative on its publishing, notably the SIO Board of Directors Members who contributed.
|
|
|
|
 |
|
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.
|
|
Get Ready for IO Awareness Week
SIO is gearing up for the inaugural IO Awareness Week, taking place 25-31 October 2021.
This dedicated week is an annual campaign to increase awareness of the field of interventional oncology and the benefits of IO therapies for cancer patients.
We are beyond excited to spread the word of IO, and we hope you will join us in celebrating the first-ever IO Awareness Week. Visit our brand-new website to learn how you can participate!
|
|
|
|
|
.INDUSTRY NEWS
Circulating DNA Changes Are Predictive of Disease Progression After Transarterial Chemoembolization
International Journal of Cancer via PubMed
Transarterial chemoembolization (TACE) is used to treat patients with unresectable hepatocellular carcinoma (HCC). We evaluated the clinical impact of a-fetoprotein (AFP) and circulating cell-free and tumor DNA (cfDNA and ctDNA) changes around the TACE procedure. This prospective monocentric study enrolled consecutive patients treated with TACE, with samples collected at baseline (D-1), day 2 (D+2) and 1 month (M+1) after TACE. cfDNA was quantified by the fluorometric method, and ctDNA was quantified by digital polymerase chain reaction designed for two hotspot TERT mutations.
|
|
Optimal Timing of Combining Sorafenib With Trans-Arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Meta-Analysis
Translational Oncology
The combination therapy of trans-arterial chemoembolization (TACE) and sorafenib were proved to be one of the effective methods for intermediate and advanced hepatocellular carcinoma (HCC). Although it has been confirmed that the combination therapy can prolong survival for advanced HCC effectively, the therapeutic efficacy and safety are still controversial and the clinical value has not been determined. This meta-analysis aims to evaluate the efficacy and safety of combination therapy and discuss the optimal timing of combination for better clinical benefits.
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
